Variant Summary
- Also known as
- KIAA1549-BRAF
- HGVS
- —
- Variant Type(s)
- transcript_fusion
- Evidence Items
- 12
Evidence Level Distribution
Level B: 4Level C: 3Level D: 5
Evidence Items
Showing CIViC evidence rows where gene = KIAA1549::BRAF and variant = Fusion.
| Level | Type | Direction | Significance | Disease | Drugs | Rating |
|---|---|---|---|---|---|---|
| B | Diagnostic | Supports | Positive | Pilocytic Astrocytoma | 5 | |
| B | Prognostic | Supports | Better Outcome | Childhood Low-grade Glioma | 4 | |
| B | Prognostic | Supports | Better Outcome | Childhood Low-grade Glioma | 4 | |
| B | Diagnostic | Supports | Positive | Pilocytic Astrocytoma | 4 | |
| D | Oncogenic | Supports | Oncogenicity | Pilocytic Astrocytoma | 3 | |
| D | Predictive | Supports | Sensitivity/Response | Childhood Pilocytic Astrocytoma | Trametinib | 3 |
| C | Predictive | Supports | Sensitivity/Response | Spindle Cell Sarcoma | Sorafenib,Bevacizumab,Temsirolimus | 2 |
| D | Predictive | Supports | Sensitivity/Response | Childhood Low-grade Glioma | Trametinib,Everolimus | 2 |
| C | Predictive | Supports | Sensitivity/Response | Spindle Cell Sarcoma | Bevacizumab,Sorafenib,Temsirolimus | 2 |
| D | Predictive | Supports | Resistance | Childhood Pilocytic Astrocytoma | Vemurafenib,Sorafenib | 2 |
| D | Predictive | Supports | Sensitivity/Response | Childhood Pilocytic Astrocytoma | Selumetinib | 2 |
| C | Predictive | Supports | Sensitivity/Response | Skin Melanoma | Trametinib | 1 |